Breaking Finance News

Mereo Biopharma Group Ltd (LON:MPH) target price held steady at 600.00GBX, reported today by Cantor Fitzgerald

In an issued report on 9/16/2016 Cantor Fitzgerald held steady the target price of Mereo Biopharma Group Ltd (LON:MPH) at 600GBX indicating a possible upside of 1.03%.

On 9/05/2016, Cantor Fitzgerald released a statement for Mereo Biopharma Group Ltd(LON:MPH) upped the target price from 0.00GBX to 600.00GBX that suggested an upside of 0.95%.

Just yesterday Mereo Biopharma Group Ltd (LON:MPH) traded 2.28% lower at 295.00GBX. The company’s 50-day moving average is 308.81GBX and its 200-day average is 306.69GBX. The last stock price close is down 2.18% from the 200-day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same period. Trade volume was was up over the average, with 6,761 shares of MPH changing hands over the typical 5,154 shares..

Performance Graph:

Mereo Biopharma Group Ltd (LON:MPH)

With a total market value of 0.0 GBX, Mereo Biopharma Group Ltd has a PE of 0 with a 52 week low of 240.00GBX and a 52 week high of 340.00GBX.

More About Mereo Biopharma Group Ltd (LON:MPH)

Mereo BioPharma Group plc, formerly Mereo BioPharma Group Limited, is a biopharmaceutical company focused on the acquisition and development of medicines that manages human health. The Company is engaged in building a pipeline of medicines, focused on rare and specialist disease areas, through the acquisition of mid-stage development programs from biopharmaceutical companies. Its initial mid-stage portfolio includes approximately three products that include BPS-804, BGS-649 and BCT-197. Its orphan disease product, BPS-804, and has completed Phase II clinical trials and is used in the treatment of osteogenesis imperfecta (OI). BGS-649 has completed Phase I clinical trials and is used in the treatment of hypogonadotrophic hypogonadism (HH). BCT-197 has also completed Phase I clinical trials and is used in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). BCT-197 is an orally active protein 38 (p38) mitogen-activated protein (MAP) inhibitor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *